Chlorogenic acid derivative as well as preparation method and application thereof

Through the development of chlorogenic acid derivatives, condensation reactions are used to generate drugs with high uric acid activity and good biocompatibility, which solves the problem of major side effects of existing anti-gout drugs and achieves a safe and efficient uric acid reduction effect.

CN118930550AActive Publication Date: 2024-11-12HUBEI HUIBO BIOTECHNOLOGY CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410985904.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-12
Estimated Expiration
2044-07-23

AI Technical Summary

Technical Problem

Existing anti-gout drugs have serious toxic side effects, especially benzylbromalone, which can lead to liver damage and adverse neurological reactions, leading to the urgent need to develop alternative drugs that are biocompatible based on natural products.

Method used

Develop a chlorogenic acid derivative, which is used to condensate chlorogenic acid and 4-aminopyrazolo[3,4-d]pyrimidine in the DCC/DMAP catalyst system to produce high uric acid-reducing activity and good biocompatibility Sexual drugs.

Benefits of technology

It achieved a significant reduction in uric acid at a dose of 5-20 mg/kg, and at the same time it had almost zero biological toxicity, and was significantly better than traditional drugs at a lower dose of medicine, providing a safe and efficient gout treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930550A_ABST
    Figure CN118930550A_ABST
Patent Text Reader

Abstract

The invention discloses a chlorogenic acid derivative as well as a preparation method and application thereof. The chlorogenic acid derivative has a molecular expression of the following structure, is prepared from chlorogenic acid and 4-aminopyrazolo [3, 4-d] pyrimidine through a reaction, and has a good application prospect as a uric acid lowering drug. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a drug derivative based on a natural product, and in particular to a chlorogenic acid derivative and a preparation method and application thereof. Background Art

[0002] With the rapid economic development, people's living standards have significantly improved. The number of patients with hyperuricemia and gout, commonly known as "rich diseases", has increased year by year, and the age of patients is getting younger. Gout is a purine metabolism disorder, which is manifested by reduced uric acid excretion and / or increased uric acid production. It can develop into uremia, renal failure, arteriosclerosis, coronary heart disease, stroke, etc., and can be life-threatening in severe cases.

[0003] At present, the prevention of hyperuricemia and gout mainly involves limiting high-purine foods and controlling alcohol consumption. In terms of treatment, it is necessary to control acute attacks of arthritis and treat hyperuricemia for a long time to prevent the deposition of tophi. Chemical drugs are divided into two categories: those for treating gouty arthritis and those for correcting hyperuricemia. The former include colchicine, nonsteroidal anti-inflammatory drugs, and glucocorticoids, which can quickly and effectively relieve pain and reduce inflammation; the latter include probenecid, benzbromarone (promoting the excretion of uric acid), and allopurinol (inhibiting the production of uric acid). However, these drugs have many adverse reactions, and benzbromarone can cause severe liver damage and adverse reactions of the nervous system. Allopurinol is the only xanthine oxidase inhibitor used clinically. It can inhibit the production of uric acid by inhibiting xanthine oxidase, but its presence can cause skin allergies, liver damage, life-threatening hypersensitivity syndrome and other toxic side effects.

[0004] In response to the serious toxic and side effects of existing anti-gout drugs, the development of new alternative drugs based on natural products with good biocompatibility has become a hot topic and scientific research challenge. Summary of the invention

[0005] In order to solve the above technical problems, the present invention provides a chlorogenic acid derivative and a preparation method and application thereof.

[0006] The present invention first proposes a chlorogenic acid derivative having the following molecular structure expression:

[0007]

[0008] Chlorogenic acid is a phenolic acid active substance with multiple pharmacological activities such as free radical scavenging, anti-inflammatory, antiviral, and immunomodulatory. It is widely present in plants such as chicory, stevia, and dandelion. The present invention uses chlorogenic acid as a raw material for drug structure design. While retaining the main molecular structure of chlorogenic acid, a chlorogenic acid derivative with good biocompatibility and high uric acid lowering activity is developed, which is expected to have good application in uric acid lowering drugs and preparations.

[0009] Secondly, the present invention also provides a method for preparing a chlorogenic acid derivative, comprising the following steps:

[0010]

[0011] Chlorogenic acid and 4-aminopyrazolo[3,4-d]pyrimidine are used as raw materials and a condensation reaction is carried out in a solvent to generate a chlorogenic acid derivative.

[0012] As a preferred embodiment of the preparation method of the present invention, the molar ratio of chlorogenic acid to 4-aminopyrazolo[3,4-d]pyrimidine is 1:(0.9-1.2), for example, 1:0.9, 1:0.95, 1:1, 1:1.05, 1:1.1, 1:1.15, etc.;

[0013] Preferably, the solvent is selected from one or more of dichloromethane, chloroform, tetrahydrofuran, acetonitrile, ethanol and ethyl acetate.

[0014] As a preferred embodiment of the preparation method of the present invention, the condensation reaction is carried out in the presence of a DCC / DMAP catalyst system.

[0015] As a preferred embodiment of the preparation method of the present invention, the DCC / DMAP catalyst system is composed of dicyclohexylcarbodiimide and 4-dimethylaminopyridine in a molar ratio of 1:(0.2-0.5), and the molar ratio of the two is, for example, 1:0.25, 1:0.3, 1:0.35, 1:0.4, 1:0.45, etc.;

[0016] Preferably, the amount of dicyclohexylcarbodiimide used is 1-1.5 times the molar amount of chlorogenic acid, for example, 1.1 times, 1.2 times, 1.3 times, 1.4 times, etc.

[0017] As a preferred embodiment of the preparation method of the present invention, it is characterized in that the reaction conditions of the condensation reaction are stirring the reaction at room temperature for 12-24 hours, such as 14 hours, 15 hours, 18 hours, 20 hours, 22 hours, etc.

[0018] As a preferred embodiment of the preparation method of the present invention, after the reaction is completed, the insoluble matter is first filtered out, and then diluted hydrochloric acid is added to extract the organic phase, which is then purified to obtain the desired product.

[0019] As a preferred embodiment of the preparation method of the present invention, the concentration of the dilute hydrochloric acid is 0.1-2 mol / L, for example, 0.5 mol / L, 1 mol / L, 1.5 mol / L, 2 mol / L, etc.

[0020] The present invention does not impose any limitation on the specific purification method of the target product, which may be any one or more of distillation, water washing, recrystallization, column chromatography, or a conventional combination of these with other known separation and purification methods.

[0021] Again, the present invention provides a use of the chlorogenic acid derivative as described above or the chlorogenic acid derivative prepared by the method described above in the medical field, especially in uric acid-lowering drugs or preparations.

[0022] The chlorogenic acid derivative provided by the present invention has high uric acid-lowering activity, a simple preparation method and good biocompatibility, and is expected to become a new type of therapeutic drug for hyperuricemia and gout. DETAILED DESCRIPTION

[0023] The present invention is further described below by means of specific examples. The examples described in the present invention are only used to illustrate the present invention and do not limit the scope of the present invention.

[0024] Unless otherwise specified, the raw materials and reagents in the present invention can be purchased from commercial sources.

[0025] [Example 1]

[0026]

[0027] Chlorogenic acid (0.35 g, 1 mmol), 4-aminopyrazolo[3,4-d]pyrimidine (0.14 g, 1 mmol), dicyclohexylcarbodiimide (0.21 g, 1 mmol), 4-dimethylaminopyridine (0.02 g, 0.2 mmol) were dissolved in dichloromethane (10 mL) and stirred at room temperature for 12 h. After the reaction was completed, the insoluble matter was removed by filtration, and then 1 mol / L dilute hydrochloric acid was added to extract the organic phase, which was dried over anhydrous sodium sulfate, rotary evaporated, and separated and purified by silica gel column chromatography (dichloromethane: methanol = 100: 1) to obtain the target product chlorogenic acid derivative (yield 74%).

[0028] 1H NMR (500MHz, Chloroform-d): δ13.23(s,1H), δ9.64(s,1H),8.90(s,1H),8.58(s,1H),8.41(s,1H),7.57- 7.50(m,1H),7.01(d,J=1.9Hz,1H),7.00-6.95(m,1H),6.95(d,J=9.0Hz,1H),6.80(d,J=8.3Hz,1H),6.21 (d,J=16.3Hz,1H),5.42(s,1H),5.38-5.30(m,1H),4.18(ddtd,J=7.5,6.1,5.0,3.7Hz,1H),4.11(d,J=6. 2Hz,1H),3.79(ddd,J=8.1,5.9,4.9Hz,1H),3.28(d,J=5.9Hz,1H),2.66-2.34(m,2H),2.29-1.97(m,2H).

[0029] [Example 2]

[0030] Chlorogenic acid (0.35 g, 1 mmol), 4-aminopyrazolo[3,4-d]pyrimidine (0.12 g, 0.9 mmol), dicyclohexylcarbodiimide (0.25 g, 1.2 mmol), 4-dimethylaminopyridine (0.06 g, 0.5 mmol) were dissolved in ethyl acetate (10 mL) and stirred at room temperature for 24 h. After the reaction was completed, the insoluble matter was removed by filtration, and then 0.5 mol / L dilute hydrochloric acid was added to extract the organic phase, which was dried over anhydrous sodium sulfate, rotary evaporated, and separated and purified by silica gel column chromatography (dichloromethane: methanol = 100: 1) to obtain the target product chlorogenic acid derivative (yield 72%).

[0031] [Example 3]

[0032] Chlorogenic acid (0.35 g, 1 mmol), 4-aminopyrazolo[3,4-d]pyrimidine (0.16 g, 1.2 mmol), dicyclohexylcarbodiimide (0.31 g, 1.5 mmol), 4-dimethylaminopyridine (0.04 g, 0.33 mmol) were dissolved in ethanol (10 mL) and stirred at room temperature for 18 h. After the reaction was completed, the insoluble matter was removed by filtration, and then 2 mol / L dilute hydrochloric acid was added to extract the organic phase, which was dried over anhydrous sodium sulfate, rotary evaporated, and separated and purified by silica gel column chromatography (dichloromethane: methanol = 100: 1) to obtain the target product chlorogenic acid derivative (yield 75%).

[0033] <Cytotoxicity test>

[0034] The CCK-8 method was used to test the cytotoxicity of PC12 cells, wherein the experimental group was a culture medium containing the chlorogenic acid derivative prepared in Example 1; the control group was a culture medium containing chlorogenic acid. The results showed that at a drug concentration of 0.5-20 μmol / L, there was no significant change in the OD value at 450 nm between the experimental group and the control group at the same concentration.

[0035] <In vivo animal experiments>

[0036] ① Animal preparation and grouping: Adult male SD rats were divided into 6 groups, 10 rats in each group, namely model group, low-dose experimental group, medium-dose experimental group, high-dose experimental group, positive control group, and raw material control group;

[0037] ② Drug preparation: First, prepare a 0.8wt% CMC-Na solution, dissolve the chlorogenic acid derivative prepared in Example 1 in the CMC-Na solution, and prepare low-dose experimental group solution, medium-dose experimental group solution, and high-dose experimental group solution with drug concentrations of 0.5mg / mL, 1mg / mL, and 2mg / mL, respectively; then dissolve benzbromarone in the CMC-Na solution to prepare a positive control group solution with a drug concentration of 1mg / mL; dissolve equal amounts of chlorogenic acid and 4-aminopyrazolo[3,4-d]pyrimidine in the CMC-Na solution to prepare a raw material control group solution with a total drug concentration of 1mg / mL.

[0038] ③Dosing experiment: Rats were intragastrically administered the drug at a dosage of 10 mL / kg per day according to their body weight for 7 consecutive days; the specific feeding method was as follows: the model group was given 0.8 wt% CMC-Na solution; the low-dose experimental group, medium-dose experimental group, and high-dose experimental group were given experimental group drug solutions with concentrations of 0.5 mg / mL, 1 mg / mL, and 2 mg / mL, respectively; the positive control group was given a positive control group drug solution with a concentration of 1 mg / mL; the raw material control group was given a raw material control group drug solution with a total concentration of 1 mg / mL.

[0039] ④ Sample processing and sampling: 30 minutes after the last administration on the 8th day, rats in each group were intraperitoneally injected with 50 mg / ml hypoxanthine solution (solvent is 0.8wt% CMC-Na solution) to establish a hyperuricemia model, and the dosage was 1000 mg / kg. 30 minutes after administration, the rats were immediately painlessly killed and the eyeballs were removed for blood collection. After the serum exuded, the blood was centrifuged at 15000 rpm for 4 minutes, and the upper serum was drawn into a sample tube with a cap, and the required volume was prepared with physiological saline. The blood uric acid content was measured on a Beckman LX20 fully automatic biochemical analyzer, and the data were expressed as mean ± standard deviation. The test results are shown in Table 1.

[0040] Table 1. Blood uric acid content test results

[0041]

[0042] It can be seen from the above test results that the chlorogenic acid derivatives provided by the present invention can exert the effect of lowering uric acid in a short time at a dosage of 5-20 mg / kg, and have almost zero biological toxicity; and the uric acid lowering level at a lower dosage is significantly better than that of the control group using chlorogenic acid and 4-aminopyrazolo[3,4-d]pyrimidine, which produces unexpected effect changes compared with the known technology, and the technical advantages are obvious.

[0043] The above is only a preferred embodiment of the present invention. It should be pointed out that ordinary technicians in this field can make several improvements and supplements without departing from the method of the present invention. These improvements and supplements should also be regarded as the scope of protection of the present invention.

Claims

1. A chlorogenic acid derivative, characterized in that It has the following molecular structure expression:

2. A method for preparing the chlorogenic acid derivative according to claim 1, characterized in that: The following steps are involved: Chlorogenic acid and 4-aminopyrazolo[3,4-d]pyrimidine are used as raw materials and a condensation reaction is carried out in a solvent to generate a chlorogenic acid derivative.

3. The method for preparing the chlorogenic acid derivative according to claim 2, characterized in that: The molar ratio of chlorogenic acid to 4-aminopyrazolo[3,4-d]pyrimidine is 1:(0.9-1.2); Preferably, the solvent is selected from one or more of dichloromethane, chloroform, tetrahydrofuran, acetonitrile, ethanol and ethyl acetate.

4. The method for preparing a chlorogenic acid derivative according to claim 2 or 3, characterized in that: The condensation reaction is carried out in the presence of a DCC / DMAP catalyst system.

5. The method for preparing the chlorogenic acid derivative according to claim 4, characterized in that: The DCC / DMAP catalyst system is composed of dicyclohexylcarbodiimide and 4-dimethylaminopyridine in a molar ratio of 1:(0.2-0.5); Preferably, the amount of dicyclohexylcarbodiimide used is 1-1.5 times the molar amount of chlorogenic acid.

6. The method for preparing the chlorogenic acid derivative according to any one of claims 2 to 5, characterized in that: The reaction conditions of the condensation reaction are stirring the reaction at room temperature for 12-24 hours.

7. The method for preparing a chlorogenic acid derivative according to any one of claims 2 to 6, characterized in that: After the reaction is completed, the insoluble matter is first filtered out, and then diluted hydrochloric acid is added to extract the organic phase, which is purified to obtain the desired product.

8. The method for preparing the chlorogenic acid derivative according to claim 7, characterized in that: The concentration of the dilute hydrochloric acid is 0.1-2 mol / L.

9. Use of the chlorogenic acid derivative according to claim 1 or the chlorogenic acid derivative prepared by the method according to any one of claims 2 to 8 in the field of medicine.

10. Use of the chlorogenic acid derivative according to claim 1 or the chlorogenic acid derivative prepared by the method according to any one of claims 2 to 8 in a uric acid-lowering drug or preparation.

Citation Information

Patent Citations

  • Synthesis method of chlorogenic acid derivative and antibacterial activity determination method

    CN111848537A

  • Uric acid reducing extract and preparation method and application thereof

    CN113274422A

  • Chlorogenic acid-apigenin conjugate as well as preparation method and application thereof

    CN116574081A